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Mason–Pﬁzer monkey virus (M-PMV), a D-type retrovirus
assembling in the cytoplasm, causes simian acquired immuno-
deﬁciency syndrome (SAIDS) in rhesus monkeys. Its pepsin-
like aspartic protease (retropepsin) is an integral part of the
expressed retroviral polyproteins. As in all retroviral life
cycles, release and dimerization of the protease (PR) is strictly
required for polyprotein processing and virion maturation.
Biophysical and NMR studies have indicated that in the
absence of substrates or inhibitors M-PMV PR should fold
into a stable monomer, but the crystal structure of this protein
could not be solved by molecular replacement despite
countless attempts. Ultimately, a solution was obtained in
mr-rosetta using a model constructed by players of the online
protein-folding game Foldit. The structure indeed shows a
monomeric protein, with the N- and C-termini completely
disordered. On the other hand, the ﬂap loop, which normally
gates access to the active site of homodimeric retropepsins,
is clearly traceable in the electron density. The ﬂap has an
unusual curled shape and a different orientation from both the
open and closed states known from dimeric retropepsins. The
overall fold of the protein follows the retropepsin canon, but
the C
  deviations are large and the active-site ‘DTG’ loop
(here NTG) deviates up to 2.7 A ˚ from the standard con-
formation. This structure of a monomeric retropepsin deter-
mined at high resolution (1.6 A ˚ ) provides important extra
information for the design of dimerization inhibitors that
might be developed as drugs for the treatment of retroviral
infections, including AIDS.
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1. Introduction
Mason–Pﬁzer monkey virus (M-PMV), or simian retrovirus
type 3 (SRV-3), is a D-type retrovirus (assembling in the
cytoplasm of the infected cell) that causes simian acquired
immunodeﬁciency syndrome (SAIDS) in Asian monkeys of
the genusMacaca. Its protease(PR), which is necessary for the
processing of, but is also an integral part of, the expressed
retroviral fusion polyproteins, is autocatalytically excised as a
17 kDaform thatundergoes further C-terminal processing toa
13 kDa (13PR) form. Protease activation and Gag processing
must be highly regulated in M-PMV, since the PR remains
inactive as part of the Gag-Pro and Gag-Pro-Pol polyproteins
until a late stage of virus release from the cell. The C-terminal
part, which contains a glycine-rich region called the G-patch
(Bauerova ´-Za ´branska ´ et al., 2005; Svec et al., 2004), is notnecessary for PR activity but is indispensable for the activity
of reverse transcriptase (RT) and for virus infectivity, and
most probably functions as the N-terminus of RT after the
proteolytic cleavage of the Gag-Pro-Pol polyprotein (Krizova
et al., unpublished results). In vitro, C-terminal autoprocessing
of 13PR proceeds even further,yielding a 12 kDa (12PR) form
of reduced activity (Za ´bransky ´ et al., 1998). M-PMV (and also
HIV) PR is activated under reducing conditions in a process
that is likely to involve Cys residues in the retroviral Gag
polyprotein. In its active form, retroviral PR is a pepsin-like
homodimeric enzyme (retropepsin) with an active site com-
posed of two DTG loops, each contributing one aspartate to a
water-molecule-bound nucleophilic element (Wlodawer et al.,
1989). The integrity of a retropepsin homodimer is maintained
by a  -sheet interface woven from alternating N-termini
and C-termini of the subunits, with additional contacts
contributed by two ﬂexible ﬂap loops and the catalytic triads
themselves.
Since the elucidation of its structure, HIV-1 PR has become
the most studied target for rational drug design; indeed, there
are now ten PR inhibitors that are used in the clinical treat-
ment of AIDS, which act as substrate analogues blocking the
active site of the enzyme. However, the emergence of drug-
resistant mutants calls for alternative strategies; the disruption
of PR dimerization would be an attractive possibility (Koh et
al., 2007) as it would not interfere with the functioning of host
aspartic proteases, which are single-chain proteins. However,
this potential drug-design approach has so far been unsuc-
cessful. Therefore, systems such as M-PMV PR, in which the
regulation of PR activity is important for virus replication and
has been better studied, might beneﬁt efforts aimed at inhi-
biting HIV-1 PR dimerization and the
development of a new generation of drugs
for the treatment of AIDS. Indeed, bio-
physical experiments have indicated that M-
PMV 13PR should form a monomer-domi-
nated equilibrium (shifted towards the
dimer in the presence of substrate/inhi-
bitor), in agreement with the NMR structure
of the 12PR variant (Veverka et al., 2003).
In the present study, we used a 13PR
protein (Trp1–Ala114) with C7A/C106A/
D26N mutations. The Cys!Ala substitu-
tions remove the possibility of uncontrolled
S–S aggregation and mimic the Cys-acti-
vated PR in vivo. The D26N substitution
changes the PR active site DTG triplet to
prevent autodigestion. The protein could be
crystallized in several crystal forms. Some of
the crystals were obtained in the presence of
an inhibitor added as a dimerization ‘bait’
with the intention of making the crystal
structure amenable to molecular-replace-
ment (MR) methods. The best crystals
(monoclinic P21), used in this study, with an
estimated two protein molecules in the
asymmetric unit, were grown in the presence
of a 1.2-fold molar excess of a peptidomimetic inhibitor.
However, the crystal structure resisted all MR attempts, which
utilized all available programs and existing crystallographic
models of retropepsins (full dimers and individual subunits).
The NMR model of monomeric 12PR could also not be used
to solve the crystal structure. The mr-rosetta algorithm, which
has an outstanding record of success with difﬁcult structures,
also failed to produce a solution using the existing models
(DiMaio et al., 2011). This daunting protein-folding problem
was therefore presented as a challenge to Foldit (Cooper et al.,
2010) players, who generated over one million models starting
from the NMR coordinates. One of these solutions, when
submitted to MR calculations in mr-rosetta (DiMaio et al.,
2011), did produce a plausible crystal structure (Khatib et al.,
2011) that could be easily reﬁned to an R factor of 0.169 with
excellent geometry. The details of the success of the Foldit–
Rosetta approach using a computer-game-derived model have
been described elsewhere (Khatib et al., 2011).
2. Materials and methods
2.1. Cloning, expression and purification of C7A/C106A/
D26N 13PR
The mutations were introduced into the previously
described plasmid pBPS13ATG using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene; Za ´branska ´ et al., 2007)
and veriﬁed by DNA sequencing. The expression of M-PMV
PR was carried out in Escherichia coli BL21 (DE3) cells under
previously described conditions (Za ´branska ´ et al., 2007). The
protease, which was expressed in inclusion bodies, was
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Figure 1
Stereoview of the main-chain trace of the ﬂap loop plus ﬂanking residues (Trp43–Tyr67). This
trace of the ﬂap of molecule A is shown in 2Fo   Fc electron density contoured at 1.0 . Side-
chain atoms have been omitted for clarity.renatured by solubilization in 8 M urea and stepwise dialysis
against 50 mM Tris–HCl pH 7.0, 1 mM EDTA, 0.05%
 -mercaptoethanol (buffer A) and was puriﬁed by ion-
exchange chromatography (batch method) on QAE-Sephadex
A-25 equilibrated with buffer A.
2.2. Crystallization
Prior to crystallization experiments, the protein was incu-
bated overnight with a 1.2-fold molar excess (relative to
dimeric enzyme) of a peptidomimetic inhibitor with the
sequence Pro-Tyr-Val-Pst-Ala-Met-Thr, where Pst is (3S,4S)-
4-amino-3-hydroxy-5-phenylpentanoic acid, and a Ki of
5.3 nM for wt 13PR protein. Crystallization screens were set
up manually using Crystal Screen and Crystal Screen 2
(Hampton Research; Jancarik & Kim, 1991) and the hanging-
drop vapour-diffusion technique at 292 K by mixing 1 ml
protein solution (8.5 mg ml
 1 in 10 mM Tris pH 8.5) and 1 ml
reservoir solution. Crystals grew to dimensions of 0.3   0.15  
0.15 mm within two weeks over a reservoir solution consisting
of 0.1 M imidazole pH 6.5 and 1 M sodium acetate. For
cryoprotection, the crystal was transferred to a solution
consisting of the crystallization mother liquor supplemented
with 15%(v/v) glycerol.
2.3. Data collection and processing
X-ray diffraction data were collected at 100 K on a MAR
CCD 165 mm detector system using synchrotron radiation
on EMBL/DESY (Hamburg) beamline X13. Integration,
scaling and merging of the intensity data was carried out in the
XDS package (Kabsch, 2010). The unit-cell parameters and
Bravais lattice were determined using the COLSPOT and
IDXREF subroutines in XDS. The intensities were reduced to
structure-factor amplitudes by the method of French & Wilson
(1978) and then converted to MTZ format using the F2MTZ
and CAD routines of CCP4( W i n net al., 2011). Space group,
unit-cell and data-collection parameters are summarized in
Table 1.
2.4. Structure solution and refinement
A model generated by Foldit (Cooper et al., 2010) players
(Khatib et al., 2011) from the NMR coordinates 1nso (Veverka
et al., 2003) successfully solved the structure in mr-rosetta
(DiMaio et al., 2011). An initial atomic model of the structure
was autobuilt and reﬁned in PHENIX (Adams et al., 2010).
Manual rebuilding of the model and divining of water mole-
cules was performed in Coot (Emsley & Cowtan, 2004).
Maximum-likelihood structure reﬁnement was carried out in
PHENIX (Adams et al., 2010) using all intensity data, with the
exception of 1070 reﬂections (5%) ﬂagged for cross-validation
purposes. No   cutoff was applied. Successive rounds of
manual rebuilding and reﬁnement of the initial model resulted
in R and Rfree values of 0.2715 and 0.2786, respectively. The
next ten cycles of simulated-annealing reﬁnement in phenix.-
reﬁne lowered the R factor to 0.2300. Implementation of TLS
parameters, selected according to the TLSMD server (Painter
& Merritt, 2005), and addition of H atoms at riding positions
as a ﬁxed contribution to Fc lowered the R factor below 0.2.
Optimization of X-ray/stereochemistry weighting in PHENIX,
reﬁnement of the occupancies of some water molecules and
several rounds of manual modelling resulted in ﬁnal R and
Rfree values of 0.1694 and 0.2124, respectively. The ﬁnal model
consisted of residues 9–103 of chain A, residues 9–102 of chain
B and 154 water molecules. The reﬁnement statistics are given
in Table 1. Structural illustrations were prepared with PyMOL
(DeLano, 2002).
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Table 1
Data-collection and structure-reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
Data collection
Crystal dimensions (mm) 0.30   0.15   0.15
Space group P21
Unit-cell parameters (A ˚ ,  ) a = 26.76, b = 86.62,
c = 39.31,   = 104.6
Solvent content (%) 28.1
Temperature (K) 100
X-ray source EMBL/DESY X13
Wavelength (A ˚ ) 0.8086
Oscillation angle ( )0 . 5
No. of frames 456
Resolution (A ˚ ) 43.3–1.63 (1.73–1.63)
Mosaicity ( ) 0.28
Rint† 0.068 (0.752)
Rmeas‡ 0.076 (0.860)
hI/ (I)i 14.9 (1.9)
Reﬂections
Measured 99683
Unique 21369
Completeness (%) 99.0 (96.3)
Multiplicity 4.7 (4.2)
Wilson B factor (A ˚ 2) 26.0
Reﬁnement
Resolution (A ˚ ) 28.6–1.63
No. of reﬂections
Work set 20295
Test set 1070
R/Rfree§ 0.1694/0.2124
Protein molecules in asymmetric unit 2
No. of atoms
Protein 1527
Water 154
hB factori (A ˚ 2)
Protein 28.4
Water 34.6
R.m.s. deviations from ideal
Bond lengths (A ˚ ) 0.018
Bond angles ( ) 1.77
Ramachandran statistics (%)
Favoured 96.8
Allowed 3.2
Outliers 0.0
PDB code 3sqf
† Rint =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl)i st h eith measure-
ment of the intensity of reﬂection hkl and hI(hkl)i is the mean intensity of reﬂection
hkl.‡ Rmeas =
P
hkl½N=ðN   1Þ 
1=2 P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where
Ii(hkl) is the ith measurement of the intensity of reﬂection hkl, hI(hkl)i is the mean
intensity of reﬂection hkl and N is the number of observations of intensity I(hkl)
(multiplicity). § R =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj, where Fobs and Fcalc are the
observed and calculated structure factors, respectively. Rfree was calculated analogously
for a randomly selected 5% of the reﬂections.3. Results and discussion
3.1. Overall characteristics of the
crystal structure
Despite its use during crystal-
lization, the inhibitor is not
present in the crystal structure
and the protein exists in a mono-
meric fold. There are two inde-
pendent 13PR molecules (A and
B) in the asymmetric unit. They
are virtually identical (C
  r.m.s.d.
of 0.18 A ˚ ) and have the general
chain topology known from the
structures of dimeric retropepsins
(Miller et al., 1989; Wlodawer et
al., 1989). The polypeptide chains
have excellent electron density
for all structural elements, except
for the N-terminus (residues
1–8) and C-terminus (104–114).
The residues forming the ﬂap
loops show increased mobility
(especially at the tips; Gln57–
Ser58), which is visible as higher
B factors, but there is no ambi-
guity about the tracing of these
loops (Fig. 1) and their identical
conformation in both molecules.
3.2. Conformation of the M-PMV
PR monomer
The secondary structure
assigned using DSSP (Kabsch &
Sander, 1983) illustrates that the
pseudo-twofold symmetry noted
earlier in the protomers of retro-
viral proteases (Miller et al., 1989)
is preserved quite well in M-PMV
PR. Notably, there is a helical
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Figure 2
Alignment of retroviral proteases. (a) Stereoview of the superposition of the C
  traces of protomers of
retroviral proteases: green and blue, M-PMV (A and B); red, HIV-1, apo form (PDB entry 3hvp); orange,
HIV-1, inhibitor complex (PDB entry 4hvp); lime, EIAV (PDB entry 2fmb); grey, M-PMV, NMR model
(PDB entry 1nso), energy-minimized (in water). (b) Structure-based sequence alignment of the M-PMV,
EIAV (PDB entry 2fmb; lowest core C
  r.m.s.d.; Table 2), FIV (PDB entry 4ﬁv; highest level of sequence
identity – 26.6%) and HIV-1 (PDB entry 3hvp) proteases. Residue numbers and secondary-structure
elements (arrows,  -strands; blue,  -helices; green, 310-helices; yellow, ﬂap loops) are marked for the
M-PMV and HIV-1 proteases. Residues that are identical in all four sequences are shown on a red
background. Disordered residues missing from the M-PMV PR structure are shown in grey.
Table 2
R.m.s.d. values (A ˚ ) for core C
  superpositions of molecule A of M-PMV PR on molecule B and on protomers of aspartic retroviral proteases, N- and C-
terminal domains of porcine pepsin and the retropepsin-like putative protease domain of the eukaryotic protein Ddi1 (PDB codes are given in
parentheses).
R.m.s.d. values for core C
  atoms are shown in the ﬁrst row and were calculated using the SSM server (Krissinel & Henrick, 2004). Values in the second row are for
all common C
  atoms (calculated in ALIGN; Cohen, 1997). The coordinates of the NMR model 1nso were energy-minimized in vacuo and in water. The following
abbreviations are used to identify different retroviral proteases: M-PMV, Mason–Pﬁzer monkey virus; HIV-1, human immunodeﬁciency virus type 1; SIV, simian
immunodeﬁciency virus; ASV, avian sarcoma virus; FIV, feline immunodeﬁciency virus; EIAV, equine infectious anaemia virus; HTLV-1, human T-cell leukaemia
virus type 1; XMRV, xenotropic murine leukaemia virus-related virus.
M-PMV
NMR (1nso) Pepsin (4pep)
B Foldit Vacuo Water
HIV-1
(3hvp)†
HIV-1
(4hvp)‡
SIV
(1yth)‡
ASV
(2rsp)†§
FIV
(4ﬁv)‡
EIAV
(2fmb)‡
HTLV-1
(3liy)‡
XMRV
(3nr6)†
Ddi1
(2i1a) N C
0.18 2.08 3.04 2.57 2.14 2.17 2.09 1.54 1.94 1.65 2.05 1.95 2.23 4.17 3.13
0.18 2.87 5.51 4.33 8.92 9.06 7.73 7.95 4.28 8.23 3.50 10.49 9.77 4.44 5.93
† Apo form. ‡ Inhibitor complex. § Flap loops missing.segment present in the N-terminal half of the protein (Leu36–
Asp38), a feature that replicates the canonical C-terminal
helix (Arg95–Leu98) but which so far has only been found in
EIAV (equine infectious anaemia virus) PR (Kervinen et al.,
1998). The C-terminal  -helix, however, is shorter than in most
retropepsins.
3.3. The flap loop
The ﬂap of M-PMV PR (residues Ile45–Ser64; Fig. 2b) has a
peculiar shape. It is not a smooth hairpin with  -type inter-
actions as in other retropepsins, but has a wide conformation
with a 310-helical segment (Gln57–Asn59) present in its
C-terminal part. The ﬂap folds upon the body of the protein
but in a way that is different from the ‘lowered’ ﬂap position
over the active site of retropepsin dimers in complex with
inhibitors (Fig. 2a). The ﬂap arm appears to be much shorter
because of the helical insertion and its blunt end. The leading/
trailing strands follow the ‘lowered’/‘open’ ﬂap traces of HIV-
1P R .T h e3 10-helix in the trailing strand resembles a helical
insertion in the ﬂap of HTLV-1 (human T-cell leukaemia virus
type-1) PR (Li et al., 2005).
3.4. The active-site loop
The active-site loop with the DTG (here NTG) triad has the
general conformation as in other pepsins. However, in the
absence of its replica, the key interactions (O
 1   Wat   O
 1,
‘ﬁreman’s grip’) are missing and the side chains of Asn26 and
Thr27 form only weak ( 3A ˚ ) contacts with water molecules.
On close comparison, the loop deviates signiﬁcantly from the
trace in HIV-1 PR (Fig. 3); the C
  deviations
culminate (2.1 A ˚ ) at Asn26, with the
departure of the O
 1 atom being even larger
(2.7 A ˚ ). This indicates that ﬁne-tuning of the
active-site geometry of retropepsins is only
possible upon dimerization.
3.5. Comparison with other models of
retropepsins
In C
  superpositions, the monomer of M-
PMV PR shows marked departures from the
subunit folds of dimeric retropepsin struc-
tures in the PDB (Table 2), with the most
pronounced differences seen in the ﬂap
region. The core C
  atoms have r.m.s.
deviations of  2A ˚ , but when all C
  atoms
are included the deviations are much larger
( 3.5 A ˚ ), explaining the failure of the MR
calculations. The ASV (avian sarcoma virus)
PR model 2rsp (Jasko ´lski et al., 1990) has an
artiﬁcially low r.m.s.d. value (1.54 A ˚ )
because of its missing ﬂaps. Of all the
retropepsin protomers (as well as homo-
logous proteins and domains; Table 2), the
closest structural homologue is the protein
from HTLV-1, but the best agreement in the
core region is with EIAV PR. The Foldit model used to solve
the structure by MR (Khatib et al., 2011) has a similar core
r.m.s.d. as the crystallographic models of retropepsins but the
value calculated for all C
  atoms is signiﬁcantly improved,
reﬂecting inter alia that the ﬂap has a generally correct
conformation.
On the background of the numerous superpositions with
crystallographic models of retropepsins (Fig.2a), the similarity
to the NMR model of M-PMV 12PR in the core region is the
lowest. Here again the ﬂap shows a widely different confor-
mation, but even with its exclusion the match of the protein
core is inferior. The alignments reported in Table 2 were
calculated for two energy-minimized models of the NMR
coordinates 1nso kindly provided by Dr Richard Hrabal.
These results explain why the NMR structure 1nso failed to
solve the crystal structure directly as an MR model. Inciden-
tally, a similar r.m.s.d. value is obtained for the only other
NMR structure of a retroviral protease (from simian foamy
virus) monomer in the PDB (PDB entry 2jys; Hartl et al.,
2008).
3.6. Structural consequences of the monomeric fold
There is no question about the absence of proper biologi-
cally competent dimers of the protease in this crystal structure
because the N- and C-terminal peptides, which are absolutely
required for and highly ordered upon dimerization, are totally
disordered. The disordered fragments include the cysteine
residues Cys7 and Cys106 (here mutated to Ala) which are
known to connect the termini under nonreducing conditions.
The existence of the Cys7–Cys106 bond has been demon-
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Figure 3
Stereoview of overlay of the active-site (D/N)TG loops of HIV-1 PR (PDB entry 3hvp, grey)
and M-PMV PR (green) based on C
  superposition of the entire molecules. The M-PMV PR
structure is shown as 2Fo   Fc electron density contoured at 1.3 .strated in monomeric M-PMV PR, but it
can be envisaged that it could be
reconﬁgured into an intermolecular
context upon dimerization, as the
canonical topology of the dimeric
interface is N(A)–C(B)–C(A)–N(B).
The novel type of interface reported
recently for XMRV (xenotropic murine
leukaemia virus-related virus) PR (Li et
al., 2011) is not applicable in this case as
it does not include the N-terminal
peptide at all. In the intramolecular
context, the Cys7–Cys106 disulﬁde
stabilizes the monomeric fold, while in
the intermolecular context it would be
expected to reinforce the dimer. Indeed,
it has been shown that in the C7A/
C106A mutant the enzymatic activity is
reduced in vitro by 60% (Za ´branska ´ et
al., 2007). However, in vivo these
mutations do not inﬂuence Gag
processing and virus infectivity. Since
the reversible oxidation of immature
M-PMV particles has been shown to
regulate PR activation in vitro (Parker
& Hunter, 2001), one can speculate that
other cysteines in the Gag polyproteins
also participate in PR activation by
modulating the conformation and
accessibility of the PR cleavage sites or
by regulating the binding of cellular
proteins that could protect the poly-
proteins from premature processing.
When the present M-PMV PR
molecule is viewed from the direction of
its absent dimerization partner, one sees
a uniformly positively charged surface
(Fig. 4). This is different from a similar
view of the HIV-1 PR protomer, in
which both charges and hydrophobic
patches are seen, and may partly explain
why in the absence of substrate/
inhibitor the M-PMV protein can stably
exist as a monomer, at least with the
D26N mutation. Fig. 4 also illustrates
that the curled ﬂap closely covers the
active-site cavity, while in the HIV-1 PR
protomer extracted from the dimeric
enzyme the cavity would be freely
accessible.
3.7. Crystal packing and molecular
interactions
The crystal packing is very dense,
with only 28.1% of the unit-cell volume
occupied by solvent (Table 1). Despite
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Figure 5
Stereoview of superposition of the C
  atoms of the HIV-1 PR protomer (PDB entry 3hvp, red) on
monomer A of M-PMV PR in the crystal structure (green). This superposition illustrates the
relation of the HIV-1 PR dimer (cartoon) to the neighbouring copies of M-PMV PR monomer B in
the crystal (blue and magenta). Bottom panel, view down the twofold axis of the HIV-1 PR dimer;
top panel, a perpendicular view with the twofold axis vertical.
Figure 4
Electrostatic potential surface of retroviral protease protomers. The M-PMV PR monomer (a)i s
shown in the same orientation and on the same scale as the HIV-1 PR protomer (b) extracted from
the dimeric molecule (PDB entry 3hvp). The complete HIV-1 PR dimer is generated by the action
of a vertical dyad, which creates a second copy facing the ﬁrst molecule on the right. In this view, the
N- and C-termini (missing in M-PMV PR) are at the bottom and the ﬂap loops are at the top. The
active-site cavity is marked by the Asn26/Asp25 residue (ball-and-stick representation). In M-PMV
PR thecavity iscompletely covered by the curled ﬂap.The area of positive potential on thisM-PMV
PR surface is inﬂuenced by the D26N substitution, but it is of note that this mutation does not
inﬂuence the tendency of the protein to fold as a monomer. The electrostatic potential (negative,
red; positive, blue) was calculated in APBS (Baker et al., 2001).this, the two protein molecules in the asymmetric unit do not
form a tight intimate dimer (see above). However, the poly-
peptide chains A and B do form crystal contacts (Fig. 5) that,
according to PISA (Krissinel & Henrick, 2007), ‘are not
strongly indicative of complex formation in solution’. These
contacts bury <800 A ˚ 2 of surface area per monomer (for
reference, HIV-1 PR dimerization buries  1700 A ˚ 2 per
monomer) and are formed in a mutual fashion by interactions
of the ﬂap loop with loop-80 (Pro86–Val90). Loop-80 is an
important element of the retropepsin structure as it partici-
pates in shaping the inhibitor-binding cavity. Another
discernible mode of crystal packing, involving an a-translated
molecule B, buries  400 A ˚ 2 in contacts that are formed nearly
exclusively by the ﬂap loops. This is an intriguing observation
because in dimeric retropepsins the ﬂaps also contribute to
protomer interactions (in addition to the N- and C-termini and
the active-site loops), especially in complexes, when they are
lowered onto the bound inhibitor. In general, the lattice
contacts in the present structure tend to shield from solvent
the face of the molecule that is normally buried upon dimer-
ization. When a dimer of HIV-1 PR (PDB entry 3hvp;
Wlodawer et al., 1989) is superposed on molecule A of the
present structure, it is obvious that the crystal-lattice aggre-
gates of M-PMV PR are different from the functional
retropepsin dimer. In particular, the active-site loops, which in
the homodimer are closely associated through a ‘ﬁreman’s
grip’ and a water-mediated (or hydroxyl-mediated) contact
between the catalytic aspartates, are far apart, with the
C
    C
  distance between the Asn26 residues being 11.4 A ˚ .I t
is evident from Fig. 5 that the monomers forming the
crystallographic aggregates of M-PMV PR remain associated
by the ﬂaps but are ‘pulled apart’ in the active site and
N-/C-terminal areas. In other words, the protomers are in close
proximity and quite well juxtaposed for productive association
but still do not interdigitate their N-/C-termini in a proper
dimeric association. One might speculate that the dimer does
not assemble by side-by-side alignment of pre-formed
monomeric proteins but is more likely to arise during the
folding process that involves the formation of the dimer
interface (from the N- and C-termini) at an early rather than
late stage, as observed for HIV-1 PR (Ishima et al., 2001).
4. Conclusions and outlook
The present structure shows that retroviral protease can fold
and exist stably as a monomer. This lends support to the
notion of using dimerization inhibitors as potential anti-
retroviral drugs. The disruption of the dimeric interface might,
for instance, be achieved by complexing the protein with an
oligopeptide with the N- and C-terminal sequences. In the case
of M-PMV PR this should be even easier because one might
exploit the potential to form a protease–inhibitor S—S bond,
but a similar strategy would also be possible for HIV-1 PR,
which contains a Cys95 residue at the C-terminus.
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